Skip to content
BEANS
Phase 3 ACTION-1 Trial Shows Promise for RYZ101 - BMY
HEALTH AND WELLNESS

Phase 3 ACTION-1 Trial Shows Promise for RYZ101 - BMY

Bristol Myers Squibb reveals positive topline results from the Phase 3 ACTION-1 trial for RYZ101 in GEP-NETs.
BRISTOL MYERS SQUIBBUNITED STATESSAN DIEGOODETTE CANCER CENTRESIMRON SINGHSUNITINIB
BiopharmaWatch - FDA Calendar, PDUFA Calendar & Biotech Catalyst TrackerEuropean Medical Journal
2 articles

Coverage

2 articles

Related

BiopharmaWatch - FDA Calendar, PDUFA Calendar & Biotech Catalyst TrackerBiopharmaWatch - FDA Calendar, PDUFA Calendar & Biotech Catalyst Tracker

Phase 3 ACTION-1 Trial Shows Promise for RYZ101 - BMY